Embecta (EMBC) Stock Price

Embecta Price

NASDAQ·CLOSED
6.02
​
Market closed

Revenue at Embecta has contracted by 0.4% per year over the past 6 years to 1.08 B USD. Earnings per share have declined at 22.3% per year over the last 6 years. For Embecta, the net margin of 8.8% is down versus 35.6% a few years ago. At today's price the dividend yield works out to roughly 9.97%. The payout ratio is around 37% of earnings. The dividend has grown at 26.0% per year over the past 3 years. The consensus 12-month price target for Embecta is 5.00 USD, about 16.9% below where the stock trades today. Of 9 analysts, 0 rate the stock a buy — an overall Sell consensus.

Embecta stock price

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Embecta business model & stock analysis

Embecta Corp. generates revenue through the manufacturing and distribution of medical devices for diabetes treatment, including pen needles, syringes, and safety injection devices. Its product portfolio features sterile, single-use pen needles designed for use with insulin pens, safety pen needles with dual-end shields to prevent needlestick injuries, and sterile insulin syringes for drawing insulin from vials. The company sells these products through retail, hospital, pharmacy, and institutional channels to customers managing diabetes. The firm’s digital application, integrated with its physical products, supports diabetes management by assisting users in tracking and administering insulin. This complementary digital solution enhances the value of its device offerings, attracting both individual consumers and healthcare institutions seeking comprehensive diabetes care solutions. Embecta Corp. focuses on providing end-to-end solutions for people living with diabetes, leveraging its product range and digital tools to address key challenges in diabetes management.

Frequently asked questions about Embecta

Analysts currently set an average price target of 5.00 USD for the Embecta stock (median: 5.00 USD), implying -16.9 % versus the latest price. The consensus is based on 9 analyst ratings.

9 analysts currently rate the Embecta stock: 0 recommend buying, 5 holding and 4 selling. For 2026, analysts expect Embecta to generate revenue of 1.02 B USD and earnings per share of 1.84 USD.

Converted at the current exchange rate, the Embecta share trades at 5.49 EUR (6.02 USD).

The Embecta share (EMBC) is listed on 4 stock exchanges, including: NASDAQ (EMBC), Frankfurt (JX7.F), München (JX7.MU), Düsseldorf (JX7.DU).

The expected revenue of Embecta is 1.02 B USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Embecta is 108.67 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Embecta is currently 3.26. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Embecta stock.

The price-to-sales ratio (P/S) of Embecta is currently 0.35. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Embecta stock.

The Eulerpool Quality Score for Embecta is 3/10.

The ISIN of Embecta is US29082K1051. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Embecta is A3DGNE. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Embecta is EMBC. The ticker symbol is used to trade Embecta shares on the stock exchange.

Fair ValueTerminal
6.26 USD
Over-/UndervaluationTerminal
Fairly valued
Sector
Industry
Health Care Equipment & Supplies
Number of shares
Employees
Revenue per Employee
584,000.00 USD
Revenue growth Ø5 years
EBIT growth Ø5 years
Net Income growth Ø5 years
Website embecta.com
Currency
USD
Initial public offering
Mar 21, 2022
ISIN
US29082K1051
Cusip
29082K105
Market capitalization
356.50 M USDSmall Cap
52-Week Range
PEG
0.35
P/E ratio
P/Ee 2026
3.28
P/Ee 2027
3.42
P/Ee 2028
3.09
P/Ee 2029
2.03
P/Ee 2030
1.97
P/S
P/Se
0.35
EV/EBIT
4.06
P/B Ratio
0.60
ROE (Return on Equity)
ROA (Return on Assets)
ROCE (Return on Capital Employed)
ROIC (Return on Invested Capital)
12.24 %
Dividend
Dividend yield
9.97 %
Est. Dividend Yield
5.32 %
Payout Ratio
37.05 %
Dividend growth Ø5Y
—
Dividend payments per year
4
Dividend paid since
4 years
Dividend not reduced since
4 years
Dividend increased since
0 years
Dividend withholding tax
30.00 %
Last updated Nov 22, 2026, 3:41 AM

Embecta Peer Group

Embecta Ticker

DÜSSELDORF · JX7.DUFRANKFURT · JX7.FMUNICH · JX7.MUNASDAQ · EMBC

Embecta FIGI

EMBC:US · BBG014L7D4G1EMBC:UA · BBG0165ZPV79EMBC:UC · BBG0165ZPV88EMBC:UN · BBG0165ZPVB4EMBC:UP · BBG0165ZPVC3EMBC:UB · BBG0165ZPVF0EMBC:UM · BBG0165ZPVH8EMBC:UX · BBG0165ZPVJ6EMBC:UD · BBG0165ZPVP9EMBC:UW · BBG0165ZPVR7EMBC:UF · BBG0165ZPVS6EMBC:VY · BBG0165ZPVT5

All fundamentals and in-depth analysis of Embecta

Our stock analysis for Embecta stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Embecta. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.